Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00045331 · ClinicalTrials.gov registry record · NA
Study in Predicting Outcome of Patients Undergoing Radiation Therapy for Prostate Cancer
A NA study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- NA
- Development phase
NCT00045331: Completed NA study, sponsored by National Cancer Institute (NCI).
NCT00045331 is a NA study that has completed, run by National Cancer Institute (NCI). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00045331, a NA study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- NA
- Development phase
Study Summary
RATIONALE: Proteins found in blood and urine samples may help predict outcome and allow doctors to plan more effective treatment. PURPOSE: Diagnostic trial to study blood and urine proteins in predicting treatment outcome in patients who are undergoing radiation therapy for prostate cancer.
Interventions
- GENETIC proteomic profiling
Trial Details
| Field | Value |
|---|---|
| Start Date | 2002-08 |
| Est. Completion | 2007-10 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00045331
The ClinicalTrials.gov registry entry for NCT00045331 describes a study currently listed as completed, categorized as NA. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which proteomic profiling is the first listed.
NCT00045331 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00045331 about?
NCT00045331 is a clinical study titled "Study in Predicting Outcome of Patients Undergoing Radiation Therapy for Prostate Cancer". RATIONALE: Proteins found in blood and urine samples may help predict outcome and allow doctors to plan more effective treatment. PURPOSE: Diagnostic trial to study blood and urine proteins in predicting treatment outcome in patients who are undergoing radiation therapy for prostate cancer.
What is the current status of trial NCT00045331?
This trial is currently completed. It is a NA study. The study started on 2002-08. Estimated completion is 2007-10.
What interventions are being tested in trial NCT00045331?
The interventions under investigation include: proteomic profiling (GENETIC).
Who is sponsoring clinical trial NCT00045331?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.